Sanctuary Advisors LLC Acquires New Holdings in Qiagen (NYSE:QGEN)

Sanctuary Advisors LLC bought a new position in shares of Qiagen (NYSE:QGEN) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 15,628 shares of the company’s stock, valued at approximately $647,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Toronto Dominion Bank acquired a new position in shares of Qiagen during the second quarter worth $27,000. Riverview Trust Co purchased a new stake in Qiagen in the first quarter valued at about $28,000. Park Place Capital Corp acquired a new stake in Qiagen in the 1st quarter worth approximately $36,000. Quarry LP acquired a new stake in shares of Qiagen during the fourth quarter worth $38,000. Finally, CWM LLC grew its stake in Qiagen by 19.1% during the 1st quarter. CWM LLC now owns 2,236 shares of the company’s stock valued at $96,000 after purchasing an additional 358 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Stock Up 0.4 %

Shares of QGEN opened at $44.09 on Tuesday. The stock has a 50 day moving average price of $45.24 and a 200 day moving average price of $43.52. Qiagen has a one year low of $34.74 and a one year high of $47.44. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.46 and a current ratio of 1.77. The stock has a market capitalization of $10.06 billion, a price-to-earnings ratio of 29.59, a PEG ratio of 3.39 and a beta of 0.39.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.52 by $0.03. The business had revenue of $496.00 million during the quarter, compared to analyst estimates of $495.45 million. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The company’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.53 earnings per share. Equities research analysts forecast that Qiagen will post 2.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Robert W. Baird upped their price objective on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. upped their price objective on shares of Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 18th. Finally, Wolfe Research upgraded Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price target for the company in a research note on Thursday, June 27th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $50.25.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.